Akero Therapeutics Inc (NASDAQ: AKRO) flaunted slowness of -3.24% at $43.67, as the Stock market unbolted on Thursday, before settling in for the price of $45.13 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $17.86-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was -5.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -17.80%. This publicly-traded company’s shares outstanding now amounts to $72.38 million, simultaneously with a float of $70.59 million. The organization now has a market capitalization sitting at $3.48 billion. At the time of writing, stock’s 50-day Moving Average stood at $39.93, while the 200-day Moving Average is $30.14.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Akero Therapeutics Inc industry. Akero Therapeutics Inc’s current insider ownership accounts for 11.34%, in contrast to 86.20% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’25, this organization’s Chief Operating Officer sold 50,000 shares at the rate of 44.86, making the entire transaction reach 2,243,213 in total value, affecting insider ownership by 201,147. Preceding that transaction, on Mar 03 ’25, Company’s Senior VP, Commercial Strategy sold 1,000 for 48.09, making the whole transaction’s value amount to 48,090. This particular insider is now the holder of 33,492 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
Akero Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -17.80% and is forecasted to reach -4.75 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -6.13% through the next 5 years, which can be compared against the -5.28% growth it accomplished over the previous five years trading on the market.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 19.38. The Stock has managed to achieve an average true range (ATR) of 2.65.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.75, a figure that is expected to reach -1.01 in the next quarter, and analysts are predicting that it will be -4.75 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Now, what If we examine the latest scores posted by [Akero Therapeutics Inc, AKRO]. During the last 5-days, its volume was lower the volume of 1.51 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 9.40% While, its Average True Range was 2.51.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 60.25%, which indicates a major rise in contrast to 1.73% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.01% that was lower than 119.90% volatility it exhibited in the past 100-days period.
